BVX 1021
Alternative Names: BVX-1021; Pan-sarbecovirus Vaccine - BioVaxysLatest Information Update: 21 Nov 2022
At a glance
- Originator BioVaxys
- Developer BioVaxys; Ohio State University
- Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Coronavirus infections
Most Recent Events
- 16 Nov 2022 Preclinical pharmacodynamics data from Coronavirus infections released by BioVaxys
- 17 Mar 2022 Preclinical trials in Coronavirus infections in New Zealand (Parenteral)
- 08 Dec 2021 BioVaxys files a patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses